Skip to content
Search

Latest Stories

Asda forecourts business to be sold to EG Group for £750m

THE Issa brothers and TDR Capital will sell Asda's petrol forecourts business to EG Group, which they also own, for £750 million ($1.03 billion) after they complete their deal to buy the British supermarket group from Walmart.

They said on Wednesday(3) that completion of the Asda acquisition was expected later this month.


In October, the Issa brothers and TDR agreed to buy a majority stake in Asda in a deal which gave the group an enterprise value of £6.8bn ($9.30bn).

In addition to selling Asda's forecourts business the Issa brothers and TDR plan to sell some of Asda's distribution assets to institutional real estate investors.

EG Group operates more than 6,000 forecourts globally. It said it expects the petrol station takeover to close in the second quarter, assuming the acquisition of Asda is cleared by the UK's competition regulator.

US giant Walmart, which has owned Asda since 1999, will retain a minority interest in the Big four grocer once the takeover gets the go ahead, reports said.

The takeover will mark the first time the supermarket chain has been under British ownership since 1999.

According to reports, the new Asda board will now comprise of Mohsin and Zuber Issa, TDR Capital partners Manjit Dale and Gary Lindsay, and Walmart executive vice president and chief financial officer Chris Nicholas. Asda chief executive Roger Burnley will also join the board.

Walmart put the chain on the market last July, a year after the UK's competition watchdog blocked a merger with rival chain Sainsbury's.

Currently, the competition markets authority (CMA) is investigating whether the latest takeover will head to higher prices for consumers. An outcome is expected in three months.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less